[go: up one dir, main page]

HRP20131057T1 - Cjepivni pripravci koji sadrže saponin kao adjuvans - Google Patents

Cjepivni pripravci koji sadrže saponin kao adjuvans Download PDF

Info

Publication number
HRP20131057T1
HRP20131057T1 HRP20131057TT HRP20131057T HRP20131057T1 HR P20131057 T1 HRP20131057 T1 HR P20131057T1 HR P20131057T T HRP20131057T T HR P20131057TT HR P20131057 T HRP20131057 T HR P20131057T HR P20131057 T1 HRP20131057 T1 HR P20131057T1
Authority
HR
Croatia
Prior art keywords
immunogenic preparation
mpl
accordance
intended
immunogenic
Prior art date
Application number
HRP20131057TT
Other languages
English (en)
Inventor
Pierre Vandepapeliere
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20131057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0525321.6A external-priority patent/GB0525321D0/en
Priority claimed from GB0609902A external-priority patent/GB0609902D0/en
Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en
Priority claimed from GB0620337A external-priority patent/GB0620337D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20131057T1 publication Critical patent/HRP20131057T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (13)

1. Imunogeni pripravak koji sadrži antigen uzveden iz citomegalovirusa (CMV) u kombinaciji s adjuvansom, naznačen time što navedeni adjuvans sadrži imunološki aktivnu saponinsku frakciju dobivenu iz kore drveta Quillaja saponaria Molina, prisutnu u obliku liposoma, i lipopolisaharid, gdje su i navedena saponinska frakcija i navedeni lipopolisaharid prisutni u pripravku u količini između 1 µg i 30 µg po dozi, namijenjenom upotrebi kao medikament za ljude.
2. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen sprječavanju infekcije i/ili bolesti koju uzrokuje citomegalovirus.
3. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što adjuvans dodatno sadrži sterol, te što je omjer saponin:sterol 1:1 do 1:100 tež./tež..
4. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je imunološki aktivna saponinska frakcija QS21.
5. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je navedeni sterol kolesterol.
6. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je navedeni lipopolisaharid derivat lipida A.
7. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je navedeni derivat lipida A 3D-MPL.
8. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je saponin QS21, lipopolisaharid je 3D-MPL, a svaki od QS21 i 3D-MPL je prisutan u količini od 20-30 µg po dozi.
9. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je svaki od QS21 i 3D-MPL prisutan u količini od 25 µg po dozi.
10. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je saponin QS21, lipopolisaharid je 3D-MPL, a svaki od QS21 i 3D-MPL je prisutan u količini od 5-15 µg po dozi.
11. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je svaki od QS21 i 3D-MPL prisutan u količini od 10 µg po dozi.
12. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je CMV antigen ljudski antigen.
13. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je CMV antigen gB, ili njegovi derivati.
HRP20131057TT 2005-12-13 2013-11-06 Cjepivni pripravci koji sadrže saponin kao adjuvans HRP20131057T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0525321.6A GB0525321D0 (en) 2005-12-13 2005-12-13 Novel compositions
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine

Publications (1)

Publication Number Publication Date
HRP20131057T1 true HRP20131057T1 (hr) 2013-12-06

Family

ID=37876836

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20120136T HRP20120136T1 (hr) 2005-12-13 2006-12-12 Imunogeni pripravak koji sadrži adjuvans
HRP20131057TT HRP20131057T1 (hr) 2005-12-13 2013-11-06 Cjepivni pripravci koji sadrže saponin kao adjuvans
HRP20140484TT HRP20140484T1 (hr) 2005-12-13 2014-05-28 Cjepivni pripravci koji sadrže saponinski adjuvans

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20120136T HRP20120136T1 (hr) 2005-12-13 2006-12-12 Imunogeni pripravak koji sadrži adjuvans

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20140484TT HRP20140484T1 (hr) 2005-12-13 2014-05-28 Cjepivni pripravci koji sadrže saponinski adjuvans

Country Status (28)

Country Link
US (3) US20080279926A1 (hr)
EP (6) EP2364723B1 (hr)
JP (2) JP5461015B2 (hr)
KR (1) KR101363879B1 (hr)
CN (3) CN102631670A (hr)
AR (1) AR058543A1 (hr)
AT (1) ATE542543T1 (hr)
AU (1) AU2006325377B2 (hr)
BR (1) BRPI0619795B8 (hr)
CA (1) CA2633008C (hr)
CR (2) CR10101A (hr)
CY (3) CY1112589T1 (hr)
DK (3) DK1959992T3 (hr)
EA (2) EA014353B1 (hr)
ES (6) ES2479165T3 (hr)
HR (3) HRP20120136T1 (hr)
IL (2) IL191703A (hr)
MA (1) MA30023B1 (hr)
MY (1) MY145943A (hr)
NO (1) NO20082472L (hr)
NZ (2) NZ568825A (hr)
PE (1) PE20071098A1 (hr)
PL (3) PL2364720T3 (hr)
PT (3) PT2364720E (hr)
SG (2) SG10201405533TA (hr)
SI (3) SI2364724T1 (hr)
TW (1) TWI457133B (hr)
WO (1) WO2007068907A2 (hr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1962899T1 (sl) 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
PL2032163T3 (pl) 2006-06-15 2013-06-28 Novartis Ag Wielodawkowa szczepionka przeciwko grypie o małej zawartości adiuwanta
ES2626662T3 (es) 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EP2045263A1 (en) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands
EP3109258B1 (en) * 2007-12-24 2019-01-23 ID Biomedical Corporation of Quebec Recombinant rsv antigens
CA2752809A1 (en) * 2009-02-17 2010-08-26 Glaxosmithkline Biologicals Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
US20110305727A1 (en) 2009-07-15 2011-12-15 Novartis Ag Rsv f protein compositions and methods for making same
EP2515938A4 (en) * 2009-12-22 2013-08-28 Sanofi Pasteur Ltd IMMUNOGENIC COMPOSITIONS
CN101791401B (zh) * 2009-12-31 2012-04-18 中国水产科学研究院黄海水产研究所 鱼用浸泡疫苗多组合佐剂及其应用和使用方法
MY156697A (en) 2010-01-27 2016-03-15 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
JP2017071615A (ja) * 2010-10-27 2017-04-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 神経障害を治療するための免疫原性組成物及び方法
ES2782119T3 (es) 2011-05-13 2020-09-10 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
SG194733A1 (en) * 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CA2850857C (en) * 2011-10-06 2022-07-26 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
NZ704490A (en) * 2012-08-16 2017-07-28 Pfizer Glycoconjugation processes and compositions
AR093712A1 (es) * 2012-12-05 2015-06-17 Glaxosmithkline Biologicals Sa Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
CA2919773A1 (en) * 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
AU2014330336A1 (en) 2013-10-03 2016-03-17 Nitto Denko Corporation Mucosal vaccine composition
CA2923026A1 (en) * 2013-10-03 2015-04-09 Nitto Denko Corporation Nasal mucosal vaccine composition
TW201601750A (zh) * 2013-10-03 2016-01-16 Nitto Denko Corp 注射疫苗組合物
BR112016006245A2 (pt) * 2013-10-03 2017-08-01 Nitto Denko Corp composição de vacina de mucosa
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
CA2943190A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
JP2018500322A (ja) * 2014-12-18 2018-01-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン接種
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
MY177587A (en) * 2015-09-10 2020-09-22 Inventprise Llc Multivalent vlp conjugates
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CN105770887A (zh) * 2016-03-04 2016-07-20 邓招红 一种用于hbv疫苗的佐剂及其制备方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11583578B2 (en) 2017-04-28 2023-02-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
BR112020004410A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora
JP7339942B2 (ja) * 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
US11324821B2 (en) 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
WO2019106191A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin extraction
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
TWI820099B (zh) 2018-03-28 2023-11-01 台灣浩鼎生技股份有限公司 新穎皂素佐劑及其評估方法
US11389519B2 (en) * 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3914708A1 (en) 2019-01-24 2021-12-01 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
PL3942028T3 (pl) 2019-03-18 2023-10-23 Janssen Pharmaceuticals, Inc. Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AU2020318680B2 (en) 2019-07-21 2025-04-24 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
EP4074335A4 (en) * 2019-12-13 2024-09-04 Grand Theravac Life Science (Nanjing) Co., Ltd. IMMUNOSTIMULATORY COMPOSITION AND USE THEREOF
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
HUE068985T2 (hu) 2020-01-16 2025-02-28 Janssen Pharmaceuticals Inc FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása
AU2021219652A1 (en) * 2020-02-14 2022-08-18 Merck Sharp & Dohme Llc HPV vaccine
WO2021195024A1 (en) * 2020-03-23 2021-09-30 Adjuvance Technologies, Inc. Adjuvant compounds, salt forms, and formulations
CA3181627A1 (en) * 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
WO2022056195A1 (en) * 2020-09-10 2022-03-17 The Rochester General Hospital Haemophilus infuluenzae vaccine and methods of use
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
MX2023005018A (es) * 2020-10-28 2023-05-16 Sanofi Pasteur Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos.
GB2600468A (en) 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
WO2023020994A1 (en) * 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
TW202315602A (zh) * 2021-08-19 2023-04-16 美商默沙東有限責任公司 新穎熱穩定脂質奈米粒子及其使用方法
CN116199727B (zh) * 2021-12-01 2025-04-08 上海安奕康生物科技有限公司 一种mpl三乙胺盐、其制备工艺及应用
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
CN118695869A (zh) 2022-02-14 2024-09-24 佐治亚大学研究基金会股份有限公司 泛-肺病毒疫苗组合物及其使用方法
JP2025509460A (ja) 2022-03-14 2025-04-11 ファイザー・インク アジュバントを生産するための方法
CN114767844A (zh) * 2022-04-28 2022-07-22 泰州拜奥生物技术有限公司 一种水痘-带状疱疹病毒疫苗及其应用
CN116162173B (zh) * 2022-10-28 2024-06-04 安徽农业大学 一种GnRH6-CRM197重组蛋白去势疫苗及制备方法
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
TW202500750A (zh) 2023-05-05 2025-01-01 法商賽諾菲公司 用於治療痤瘡的組成物
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025057078A1 (en) * 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US666843A (en) * 1900-07-02 1901-01-29 Eastman Kodak Co Spirit-level.
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
DE2921961C2 (de) 1979-05-30 1986-02-06 Santrade Ltd., Luzern/Lucerne Bohreinheit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
CA1339204C (en) 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
DE69031556T2 (de) 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigene sowie Verfahren zu deren Herstellung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
DE69226167T2 (de) 1991-02-15 1998-11-12 The Uab Research Foundation, Birmingham, Alabama Strukturgen von pneumokokken-protein
GB9113809D0 (en) 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ATE356142T1 (de) 1991-07-19 2007-03-15 Univ Queensland Impfstoff gegen humanes papillomavirus (typ 18)
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
DE69232265T2 (de) 1992-06-25 2002-08-08 City Of Hope, Duarte Induktion von cytolytischen t-lymphocyten mit polypeptiden des cytomegalievirus
DE122007000094I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
PT761231E (pt) * 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
AU688759C (en) 1993-03-09 2006-12-21 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
BE1007535A3 (nl) 1993-09-24 1995-07-25 Innovative Sputtering Tech Gelaagde metaalstructuur.
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
GB9409962D0 (en) 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
ES2264563T3 (es) 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US20030219453A1 (en) * 1998-03-19 2003-11-27 Smithkline Beecham Biologicals, Sa Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5688267A (en) * 1995-05-01 1997-11-18 Ep Technologies, Inc. Systems and methods for sensing multiple temperature conditions during tissue ablation
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
HUP0600442A3 (en) 1995-06-07 2007-03-28 Biochem Vaccines Inc Streptococcal heat shock proteins members of the hsp70 family
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JP2000514308A (ja) 1996-08-16 2000-10-31 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
CA2269663A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
JP2002503087A (ja) 1996-11-12 2002-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニアのｃ３結合タンパク質
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
WO1998033923A1 (en) 1997-01-30 1998-08-06 Imperial College Of Science, Technology & Medicine MUTANT msbB or htrB GENES
AR012035A1 (es) 1997-02-25 2000-09-27 Corixa Corp Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
JP3036686B2 (ja) 1997-02-27 2000-04-24 政夫 高橋 冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
BR9811262A (pt) * 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
BR9809914A (pt) 1997-06-03 2001-09-18 Connaught Lab Genes de moracella receptores de lactoferrina
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US5928215A (en) * 1997-08-14 1999-07-27 Becton, Dickinson And Acompany Syringe filling and delivery device
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) * 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
KR20010024299A (ko) 1997-09-24 2001-03-26 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 사람 보체 ｃ3 분해단백질분해효소
WO1999019479A1 (en) 1997-09-26 1999-04-22 Corixa Corporation Murine model for human carcinoma
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
TR200003498T2 (tr) 1998-04-07 2001-10-22 St. Jude Children's Research Hospital Amino asit sekansından oluşan bir polipetit, bunun aşıları ve kullanımları
ES2343492T3 (es) 1998-04-07 2010-08-02 Medimmune, Llc Derivados de proteinas neumococicas de union a colina para vacunas.
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
JP2002516251A (ja) 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
JP4503177B2 (ja) 1998-06-03 2010-07-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム モラクセラ・カタラーリス（Ｍｏｒａｘｅｌｌａｃａｔａｒｒｈａｌｉｓ）由来のＢＡＳＢ０２７タンパク質およびＢＡＳＢ０２７遺伝子、抗原、抗体、ならびに使用
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1097208A2 (en) 1998-07-14 2001-05-09 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
GB9820002D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
AU6060899A (en) 1998-09-24 2000-04-10 American Cyanamid Company Human complement c3-degrading polypeptide from (streptococcus pneumoniae)
WO2000030299A1 (en) 1998-11-17 2000-05-25 Schlumberger Technology Corporation Transmitting information over a communication link
WO2000029434A2 (en) 1998-11-19 2000-05-25 St. Jude Children's Research Hospital PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
DE69940439D1 (de) 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
EP1147190B1 (en) 1999-01-29 2010-07-14 Corixa Corporation Her-2/neu fusion proteins
GB9904559D0 (en) 1999-02-26 1999-04-21 Smithkline Beecham Biolog Novel compounds
AU3391200A (en) 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
DE60038166T2 (de) * 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
AU777856B2 (en) 1999-06-10 2004-11-04 Human Genome Sciences, Inc. Streptococcus pneumoniae proteins and vaccines
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
GB9918038D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9917977D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918208D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
GB9918302D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
US6139179A (en) 1999-09-03 2000-10-31 Davis-Standard Corporation Extruder screw having multi-channeled barrier section
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
IL153558A0 (en) 2000-06-20 2003-07-06 Shire Biochem Inc Streptococcus antigens
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
GB0019375D0 (en) 2000-08-07 2000-09-27 Int Centre Genetic Eng & Bio Method of polypeptide renaturation
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
CA2438960A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CN1678188B (zh) * 2002-07-03 2012-10-10 科勒制药集团有限公司 调节免疫反应的核酸成份
EP2269638A3 (en) * 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CA2602637A1 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
WO2006114312A2 (en) 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
DK2426141T3 (da) 2005-04-29 2014-11-10 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M tuberkuloseinfektioner
US20090035330A1 (en) * 2005-05-19 2009-02-05 Marianne Dewerchin Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant

Also Published As

Publication number Publication date
SI2364720T1 (sl) 2014-07-31
BRPI0619795B8 (pt) 2021-05-25
ES2378471T3 (es) 2012-04-12
EP1959992B1 (en) 2012-01-25
HRP20140484T1 (hr) 2014-07-04
PT2364720E (pt) 2014-06-24
EP2364721A1 (en) 2011-09-14
AU2006325377B2 (en) 2012-02-02
ATE542543T1 (de) 2012-02-15
EA200801307A1 (ru) 2008-12-30
CN103861100A (zh) 2014-06-18
EP2364721B1 (en) 2013-11-20
CR10101A (es) 2008-09-22
CR10118A (hr) 2008-08-21
EP2364722B1 (en) 2013-11-13
IL191703A (en) 2013-12-31
HK1157219A1 (en) 2012-06-29
EP2364722A1 (en) 2011-09-14
BRPI0619795A2 (pt) 2011-10-18
SG170127A1 (en) 2011-04-29
HK1118477A1 (en) 2009-02-13
EP2364720B1 (en) 2014-05-07
US10143745B2 (en) 2018-12-04
TWI457133B (zh) 2014-10-21
US20110206758A1 (en) 2011-08-25
WO2007068907A3 (en) 2007-08-09
DK2364720T3 (da) 2014-06-10
EA201001189A1 (ru) 2011-02-28
ES2445170T3 (es) 2014-02-28
PL2364720T3 (pl) 2014-09-30
ES2444623T3 (es) 2014-02-26
TW200730189A (en) 2007-08-16
PL1959992T3 (pl) 2012-06-29
DK1959992T3 (da) 2012-04-23
CA2633008A1 (en) 2007-06-21
KR101363879B1 (ko) 2014-02-21
JP5461015B2 (ja) 2014-04-02
CN103405764A (zh) 2013-11-27
JP2009519309A (ja) 2009-05-14
DK2364724T3 (da) 2013-11-11
PL2364724T3 (pl) 2014-02-28
SI2364724T1 (sl) 2013-12-31
CY1112589T1 (el) 2016-02-10
PT2364724E (pt) 2013-12-09
EP2364723B1 (en) 2014-01-15
ES2451573T3 (es) 2014-03-27
US10039823B2 (en) 2018-08-07
US20080279926A1 (en) 2008-11-13
EP1959992A2 (en) 2008-08-27
EP2364724A1 (en) 2011-09-14
JP2013056927A (ja) 2013-03-28
HRP20120136T1 (hr) 2012-03-31
BRPI0619795B1 (pt) 2019-09-10
PT1959992E (pt) 2012-03-06
CN102631670A (zh) 2012-08-15
WO2007068907A2 (en) 2007-06-21
EP2364724B1 (en) 2013-09-18
NZ568825A (en) 2012-01-12
SG10201405533TA (en) 2014-11-27
MA30023B1 (fr) 2008-12-01
EP2364720A1 (en) 2011-09-14
US20170065715A1 (en) 2017-03-09
CY1115308T1 (el) 2017-01-04
SI1959992T1 (sl) 2012-04-30
CA2633008C (en) 2019-04-30
CY1114864T1 (el) 2016-12-14
KR20080079312A (ko) 2008-08-29
MY145943A (en) 2012-05-31
EA018860B1 (ru) 2013-11-29
ES2479165T3 (es) 2014-07-23
EA014353B1 (ru) 2010-10-29
EP2364723A1 (en) 2011-09-14
IL229521A0 (en) 2013-12-31
NO20082472L (no) 2008-09-10
IL191703A0 (en) 2008-12-29
AR058543A1 (es) 2008-02-13
NZ596870A (en) 2013-06-28
ES2436645T3 (es) 2014-01-03
AU2006325377A1 (en) 2007-06-21
PE20071098A1 (es) 2007-11-07

Similar Documents

Publication Publication Date Title
HRP20131057T1 (hr) Cjepivni pripravci koji sadrže saponin kao adjuvans
JP2009519309A5 (hr)
NO20005051L (no) Adjuvantsammensetninger
HRP20160816T1 (hr) Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica
Sun et al. ISCOMs and ISCOMATRIX™
PE20120319A1 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico
BR122019026154B8 (pt) vírus da dengue atenuado, composições farmacêuticas compreendendo dito vírus, kit, vacinas tetravalente, atenuada viva e inativada contra o vírus da dengue, e métodos para preparar um vírus da dengue e uma composição farmacêutica
NO20073868L (no) Levende attenuert rotavirus vaksine for oral administrering
CA2383105A1 (en) Intranasal influenza virus vaccine
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
HRP20140488T1 (hr) Cjepivo protiv influence
MXPA02003068A (es) Adyuvante que comprende un eter o ester alquilo de polioxietileno y al menos un tensioactivo no ionico..
CL2013002106A1 (es) Composicion inmunogenica de streptococcus pneumoniae que comprende 2 o mas conjugados de sacarido capsular de diferentes serotipos; vacuna que la comprende; procedimiento de fabricacion; y su uso para tratar o prevenir enfermedades causadas por la infeccion por streptococcus pneumoniae (div.sol.n°3625-2006).
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
NZ598645A (en) New vaccine formulations comprising saponin-containing adjuvants
CU23552A1 (es) Composición vacunal
JP2016502551A5 (hr)
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
Bai et al. Development of semisynthetic saponin immunostimulants
Lacaille-Dubois Saponins as immunoadjuvants and immunostimulants
Delporte et al. Quillaja saponaria Molina
US10973900B2 (en) Dried composition